Seres Therapeutics, Inc. Revenue from Related Parties
Seres Therapeutics, Inc. (MCRB) reported Revenue from Related Parties of $26.92 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-06.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2019-03-06
- Seres Therapeutics, Inc. revenue from related parties for the quarter ending 2018-12-31 was $10.20M, a 233.64% increase year-over-year.
- Seres Therapeutics, Inc. revenue from related parties for the quarter ending 2018-09-30 was $8.68M, a 62.27% decline year-over-year.
- Seres Therapeutics, Inc. revenue from related parties for the quarter ending 2018-06-30 was $4.27M, a 41.71% increase year-over-year.
- Seres Therapeutics, Inc. revenue from related parties for the quarter ending 2018-03-31 was $3.77M, a 24.91% increase year-over-year.
- Seres Therapeutics, Inc. revenue from related parties for fiscal 2018 was $26.92M, a 16.15% decline from fiscal 2017.
- Seres Therapeutics, Inc. revenue from related parties for fiscal 2017 was $32.10M, a 47.48% increase from fiscal 2016.
- Seres Therapeutics, Inc. revenue from related parties for fiscal 2016 was $21.77M.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 6 month | Revenue from Related Parties 9 month | Revenue from Related Parties 12 month |
|---|---|---|---|---|
| 2018-12-31 | $10.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $18.88M derived: sum of 2 quarters · filed 2019-03-06 | $23.15M derived: sum of 3 quarters · filed 2019-03-06 | $26.92M 10-K · filed 2019-03-06 |
| 2018-09-30 | $8.68M 10-Q · filed 2018-11-08 | $12.96M derived: sum of 2 quarters · filed 2018-11-08 | $16.72M 10-Q · filed 2018-11-08 | $19.78M derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-06-30 | $4.27M 10-Q · filed 2018-08-02 | $8.04M 10-Q · filed 2018-08-02 | $11.09M derived: sum of 3 quarters · filed 2018-08-02 | $34.11M derived: sum of 4 quarters · filed 2018-08-02 |
| 2018-03-31 | $3.77M 10-Q · filed 2018-05-09 | $6.82M derived: sum of 2 quarters · filed 2018-05-09 | $29.84M derived: sum of 3 quarters · filed 2018-05-09 | $32.85M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | $3.06M 10-K · filed 2018-03-08 | $26.07M derived: sum of 2 quarters · filed 2018-03-08 | $29.09M derived: sum of 3 quarters · filed 2018-03-08 | $32.10M 10-K · filed 2018-03-08 |
| 2017-09-30 | $23.02M 10-K · filed 2018-03-08 | $26.03M derived: sum of 2 quarters · filed 2018-03-08 | $29.04M 10-Q · filed 2017-11-08 | $32.08M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-06-30 | $3.01M 10-K · filed 2018-03-08 | $6.03M 10-Q · filed 2017-08-03 | $9.07M derived: sum of 3 quarters · filed 2018-05-09 | $22.08M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-03-31 | $3.02M 10-Q · filed 2018-05-09 | $6.05M derived: sum of 2 quarters · filed 2018-05-09 | $19.07M derived: sum of 3 quarters · filed 2018-05-09 | $22.07M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $3.04M 10-K · filed 2018-03-08 | $16.05M derived: sum of 2 quarters · filed 2018-03-08 | $19.06M derived: sum of 3 quarters · filed 2018-03-08 | $21.77M 10-K · filed 2018-03-08 |
| 2016-09-30 | $13.02M 10-K · filed 2018-03-08 | $16.02M derived: sum of 2 quarters · filed 2018-03-08 | $18.73M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $3.00M 10-K · filed 2018-03-08 | $5.71M 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | $2.71M 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |